{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:31:39Z","timestamp":1792297899607,"version":"4.4.0"},"reference-count":59,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the management of vitiligo is still challenging. As vitiligo is a chronic disease limited to the skin, topical rather than systemic therapies may be preferable (especially among patients with localised lesions) to avoid the long\u2010term side\u2010effects of the latter. A topical formulation of ruxolitinib, a selective JAK1\/2 inhibitor, has recently been approved in the United States for the treatment of non\u2010segmental vitiligo in patients aged &gt;12\u2009years based on data from the phase III TRuE\u2010V1 and TRuE\u2010V2 clinical trials. The aim of this review is to describe the current evidence concerning the efficacy and safety of topical ruxolitinib in the treatment of vitiligo, and discuss issues regarding its use in younger children and pregnant or breastfeeding women, as well as the duration and durability of treatment. The promising results obtained so far suggest that 1.5% ruxolitinib cream is an effective means of treating vitiligo.<\/jats:p>","DOI":"10.1111\/jdv.19162","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T02:25:26Z","timestamp":1683339926000},"page":"2222-2230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Topical ruxolitinib: A new treatment for vitiligo"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-318X","authenticated-orcid":false,"given":"G.","family":"Tavoletti","sequence":"first","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-2370","authenticated-orcid":false,"given":"G.","family":"Avallone","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"},{"name":"Department of Medical Sciences, Dermatology Clinic University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-8873","authenticated-orcid":false,"given":"C.","family":"Conforti","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Maggiore Hospital of Trieste  Trieste Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roccuzzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatology Clinic University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-849X","authenticated-orcid":false,"given":"C. A.","family":"Maronese","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-9586","authenticated-orcid":false,"given":"P.","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatology Clinic University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zalaudek","sequence":"additional","affiliation":[{"name":"Dermatology Clinic Maggiore Hospital of Trieste  Trieste Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"A. V.","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"S.","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Dermatology Clinic University of Turin  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7163-1035","authenticated-orcid":false,"given":"S.","family":"Alberti\u2010Violetti","sequence":"additional","affiliation":[{"name":"Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation Universit\u00e0 degli Studi di Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.11"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60763-7"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00032.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.039"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18257"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13531"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18134"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506103"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14435"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.08.005"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18005"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00610-x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119889"},{"key":"e_1_2_11_17_1","unstructured":"Food and Drug Administration.Ruxolitinib cream \u2013 NDA multi\u2010disciplinary review and evaluation. [accessed 2022 Dec 5]. Available from:https:\/\/www.fda.gov\/media\/154307\/download"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.023"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.047"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.05.1093"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828"},{"key":"e_1_2_11_24_1","unstructured":"A study to evaluate the mechanism of action of ruxolitinib cream in subjects with vitiligo (TRuE\u2010V MOA). NCT04896385. [accessed 2022 Dec 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04896385?cond=TRuE\u2010V+MOA&draw=2&rank=1"},{"key":"e_1_2_11_25_1","unstructured":"A study to evaluate the safety and efficacy of ruxolitinib cream with phototherapy in participants with vitiligo. NCT05247489. [accessed 2022 Dec 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05247489?cond=NCT05247489&draw=2&rank=1"},{"key":"e_1_2_11_26_1","unstructured":"Assess the long term efficacy and safety of ruxolitinib cream in participants with vitiligo. NCT04530344. [accessed 2022 Dec 5]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530344?cond=NCT04530344&draw=2&rank=1"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060"},{"key":"e_1_2_11_29_1","unstructured":"Food and Drug Administration.FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older. [accessed 2022 Dec 5]. Available from:https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010topical\u2010treatment\u2010addressing\u2010repigmentation\u2010vitiligo\u2010patients\u2010aged\u201012\u2010and\u2010older"},{"key":"e_1_2_11_30_1","unstructured":"European Medicines Agency. [accessed 2022 Dec 5]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/pip\u2010decision\/p\/0145\/2021\u2010ema\u2010decision\u201016\u2010april\u20102021\u2010agreement\u2010paediatric\u2010investigation\u2010plan\u2010granting\u2010deferral\u2010granting_en.pdf"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.335"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1735615"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.015"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000658"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11197.x"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20596"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08747.x"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00323.x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.02101.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.003"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18533"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16114"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2211886"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04215.x"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15688"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2022.2139317"},{"key":"e_1_2_11_50_1","unstructured":"Safety and efficacy of ARQ\u2010252 cream 0.3% in subjects with non\u2010segmental facial vitiligo. NCT04811131. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04811131?cond=ARQ\u2010252&draw=2&rank=1"},{"key":"e_1_2_11_51_1","unstructured":"Safety and tolerability study of cerdulatinib gel 0.37% in adults with vitiligo. NCT04103060. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04103060?cond=cerdulatinib&draw=2&rank=2"},{"key":"e_1_2_11_52_1","unstructured":"A study of ATI\u201050002 topical solution for the treatment of vitiligo. NCT03468855. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03468855?cond=ATI\u201050002&draw=2&rank=1"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"},{"key":"e_1_2_11_54_1","unstructured":"A 52\u2010week study of ritlecitinib oral capsules in adults and adolescents with vitiligo (active and stable) (Tranquillo). NCT05583526. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05583526?cond=ritlecitinib&draw=2&rank=5"},{"key":"e_1_2_11_55_1","unstructured":"Study to evaluate adverse events and change in disease activity with oral tablets of upadacitinib in adult partecipants with non\u2010segmental vitiligo. NCT04927975. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04927975?cond=upadacitinib+vitiligo&draw=2&rank=1"},{"key":"e_1_2_11_56_1","unstructured":"Evaluation of effect and tolerance of the association of baricitinib and phototherapy versus phototherapy in adults with progressive vitiligo (BARVIT). NCT04822584. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04822584?cond=baricitinib+vitiligo&draw=2&rank=1"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19022"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005127"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6952299"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T09:19:37Z","timestamp":1698225577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/jdv.19162"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19162","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"2023-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}